Hepatocellular carcinoma risk unclear after hepatitis C treatment

Relapsing-Remitting Multiple Sclerosis Benefits From Early Treatment With Cladribine
December 5, 2017
Lung Cancer Awareness Saves Lives
December 5, 2017
Show all

Hepatocellular carcinoma risk unclear after hepatitis C treatment

What is the risk of liver cancer after treatment is successful for hepatitis C?

A new study published in Journal of Hepatology found no evidence for a difference in hepatocellular carcinoma (HCC) occurrence or recurrence after sustained virological response with direct-acting antivirals (DAAs) compared with interferon-based therapy.

In this systematic review, researchers performed meta-analyses and meta-regression on 26 studies of HCC occurrence (interferon [IFN], n = 17; DAA, n = 9) and 17 studies of hepatocellular carcinoma recurrence (IFN, n = 7; DAA, n = 10) after hepatitis C curative therapy. To determine the HCC incidence rate per 100 person-years, random effects meta-analyses were used.

Compared with IFN studies, DAA studies had a shorter follow-up and older average age within the HCC occurrence studies. Researchers found that HCC occurrence was 1.14 per 100 person-years in IFN studies (95% CI, 0.86-1.52) and 2.96 per 100 person-years in DAA studies (95% CI, 1.76-4.96). After adjustment for study follow-up and age, meta-regression revealed no association between higher HCC occurrence and DAAs (relative risk [RR], 0.68; 95% CI, 0.18-2.55; P =.55).

For HCC recurrence studies, those studies investigating DAAs had shorter average follow-up but similar average age compared with IFN studies. Among DAA studies, HCC recurrence was 12.16 per 100 person-years (95% CI, 5.00-29.58) compared with 9.21 per 100 person-years for IFN studies (95% CI, 7.18-11.81). Meta-regression revealed no association between DAA therapy and HCC recurrence (RR, 0.62, 95% CI 0.11-3.45; P =.56).

Read full article: Hepatocellular carcinoma risk unclear after hepatitis C treatment – The Clinical Advisor

Read Full Article: Hepatocellular carcinoma risk unclear after hepatitis C treatment – The Clinical Advisor

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.